Maxipime ADD-Vantage Side Effects
Generic Name: cefepime, cefepime hydrochloride
Please note - some side effects for Maxipime ADD-Vantage may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Side Effects by Body System - for Healthcare Professionals
Applies to: injectable powder for injection; injectable solution
Cefepime is generally well tolerated. It has been reported that 1.5% of patients discontinued medication due to adverse events.
If diarrhea occurs which is unresponsive to discontinuation of cefepime and/or standard therapy, pseudomembranous colitis should be considered.
Higher doses (2 grams every 8 hours) have been associated with a greater incidence of side effects, including diarrhea (3%), nausea (2%), and vomiting (1%).
Gastrointestinal side effects have included colitis (including pseudomembranous colitis), diarrhea, nausea, vomiting, and oral moniliasis in 0.1% to less than 1% of patients. Abdominal pain, anorexia, stomatitis, and Clostridium difficile-associated diarrhea have also been reported.
Local side effects have included local reactions (3%), including phlebitis (1.3%) and pain and/or inflammation (0.6%), irrespective to cefepime in patients who received intravenous infusion. Infusion site reaction has also been reported.
Nervous system side effects have included headache (0.1% to less than 1%). Encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, and nonconvulsive status epilepticus have been reported during postmarketing experience, mostly in patients with renal impairment receiving higher than recommended dosages. Somnolence has also been reported.
Some cases of encephalopathy occurred in patients receiving an appropriate dosage for their degree of renal impairment.
Case reports of seizure activity, with and without convulsions, associated with cefepime have been published in the medical literature. In the vast majority of cases, the patient involved had a clinically significant degree of renal dysfunction. In each case, seizure activity abated upon the discontinuation of cefepime.
Higher doses (2 grams every 8 hours) have been associated with a greater incidence of side effects, including headache (1%).
A 66-year-old female developed acute renal failure, altered level of consciousness (Glasgow Coma Scale 6), and nonconvulsive status epilepticus after 10 days of cefepime 2 g every 8 hours. Symptoms resolved and she completely recovered 72 hours after discontinuation of cefepime.
Dermatologic side effects have included rash (1.1%), urticaria (0.1% to less than 1%), and pruritus (0.1% to less than 1%).
Higher doses (2 grams every 8 hours) have been associated with a higher incidence of side effects, including rash (4%) and pruritus (1%).
Hematological side effects have included positive Coombs' test (without hemolysis; 16.2%), increased eosinophils (1.7%), abnormal PTT (1.6%), and abnormal PT (1.4%). Decreased hematocrit, neutrophils, platelets, and white blood cells have been reported in 0.1% to less than 1% of patients. Cephalosporins as a class have been associated with aplastic anemia, hemolytic anemia, prolonged prothrombin time, hemorrhage, and pancytopenia. Epistaxis has also been reported.
Anaphylactic reactions are rare, but may occur, especially in patients with a history of penicillin allergy.
Hypersensitivity side effects have included anaphylaxis (including anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis, and thrombocytopenia) during postmarketing experience. Acute hypersensitivity myocarditis has been reported. Cephalosporin class antibiotics have been associated with allergic reactions, Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis.
Hepatic side effects have included increased ALT (2.8%), AST (2.4%), alkaline phosphatase (0.1% to less than 1%), and total bilirubin (0.1% to less than 1%). Cephalosporins as a class have been associated with hepatic dysfunction including cholestasis.
Metabolic side effects have included decreased phosphorus (2.8%) and calcium (0.1% to less than 1%). Increased calcium, phosphorus, and potassium have been reported in 0.1% to less than 1% of patients. Hypokalemia and hypomagnesemia have been reported.
Hypocalcemia was more common among elderly patients. Clinical consequences from changes in either calcium or phosphorus were not reported.
Higher doses (2 grams every 8 hours) have been associated with a greater incidence of side effects, including fever (1%).
Other side effects have included fever (0.1% to less than 1%).
Renal side effects have included increased BUN and creatinine in 0.1% to less than 1% of patients. Renal failure, mostly in patients with renal impairment who received higher than recommended doses of cefepime, has been reported. Cephalosporins as a class have been associated with renal dysfunction and toxic nephropathy.
Genitourinary side effects have included vaginitis (0.1% to less than 1%).
Respiratory side effects have included cough and dyspnea.
Cardiovascular side effects have included tachycardia.Top
- Maxipime ADD-Vantage Concise Consumer Information (Cerner Multum)
- Cefepime Prescribing Information (FDA)
- Cefepime Professional Patient Advice (Wolters Kluwer)
- cefepime MedFacts Consumer Leaflet (Wolters Kluwer)
- cefepime Injection Advanced Consumer (Micromedex) - Includes Dosage Information
- Cefepime Hydrochloride Monograph (AHFS DI)
- Maxipime Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.